Comprehensive analysis on diagnostic value of circulating miRNAs for patients with ovarian cancer

Background: Circulating microRNAs (miRNAs) are proposed as promising non-invasive diagnostic biomarkers for many cancers. However, the diagnostic value of circulating miRNAs in ovarian cancer is inconsistent in different studies. Thus we performed this meta-analysis to systematically evaluate the diagnostic value of circulating miRNAs in ovarian cancer. Methods: Eligible studies that were published prior to 30 June 2017 were searched from the PubMed, EMBASE, Cochrane Library, and Chinese National Knowledge Infrastructure. All analyses were performed using STATA 12.0 software. A bivariate regression was used to calculate pooled diagnostic accuracy estimates. Results: A total of 36 studies from 16 publications were included in this meta-analysis. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio of circulating miRNAs for ovarian cancer diagnosis were 0.76 (95% confidence intervals (CI): 0.69, 0.81), 0.81 (95% CI 0.74, 0.87), 4.00 (95% CI 2.70, 5.30), 0.30(95% CI 0.24, 0.37) and 13.00 (95% CI 9.00, 19.00), respectively. The area under the summary receiver operating characteristic curve was 0.85 (95% CI 0.82, 0.88). Subgroup analyses showed that multiple miRNA assays yielded better diagnostic characteristics than a single miRNA assay, and plasma miRNAs were better than serum miRNAs for ovarian cancer detection. Conclusion: Circulating miRNAs, especially the combination of multiple circulating miRNAs, are promising biomarkers for the diagnosis of ovarian cancer. However, further large-scale prospective studies are necessary to validate the applicability of the miRNAs in the early detection of ovarian cancer.

Download Full-text

Diagnostic value of oncofetal miRNAs in cancers: A comprehensive analysis of circulating miRNAs in pan-cancers and UCB

Cancer Biomarkers ◽

10.3233/cbm-203085 ◽

2021 ◽

pp. 1-18

Author(s):

Xin Zhou ◽

Cheng Liu ◽

Yin Yin ◽

Cheng Zhang ◽

Xuan Zou ◽

...

Keyword(s):

Expression Patterns ◽

Diagnostic Value ◽

Comprehensive Analysis ◽

Detection Methods ◽

Plasma Samples ◽

Circulating Mirnas ◽

Serum Samples ◽

Chinese Populations ◽

Non Invasive ◽

Plasma Mirnas

BACKGROUND: Circulating miRNAs are promising biomarkers for detection of various cancers. As a “developmental” disorder, cancer showed great similarities with embryos. OBJECTIVE: A comprehensive analysis of circulating miRNAs in umbilical cord blood (UCB) and pan-cancers was conducted to identify circulating miRNAs with potential for cancer detection. METHODS: A total of 3831 cancer samples (2050 serum samples from 15 types of cancers and 1781 plasma samples from 13 types of cancers) and 248 UCB samples (120 serum and 128 plasma samples) with corresponding NCs from Chinese populations were analyzed via consistent experiment workflow with Exiqon panel followed by multiple-stage validation with qRT-PCR. RESULTS: Thirty-four serum and 32 plasma miRNAs were dysregulated in at least one type of cancer. Eighteen serum and 16 plasma miRNAs were related with embryos. Among them, 9 serum and 8 plasma miRNAs with consistent expression patterns between pan-cancers and UCB were identified as circulating oncofetal miRNAs. Retrospective analysis confirmed the diagnostic ability of circulating oncofetal miRNAs for specific cancers. And the oncofetal miRNAs were mainly up-regulated in tissues of pan-cancers. CONCLUSIONS: Our study might serve as bases for the potential application of the non-invasive biomarkers in the future clinical.

Download Full-text

DIAGNOSTIC VALUE OF SERUM PROTEOMIC PROFILING IN PATIENTS WITH HIGH GRADE SEROUS OVARIAN CANCER

10.26226/morressier.5770e29cd462b80290b4bf9b ◽

2016 ◽

Author(s):

Jian-Qing Zhu

Keyword(s):

Ovarian Cancer ◽

Diagnostic Value ◽

High Grade ◽

Serous Ovarian Cancer ◽

Proteomic Profiling

Download Full-text

Diagnostic value of [18F]FDG PET/MRI for staging in patients with ovarian cancer

EJNMMI Research ◽

10.1186/s13550-020-00712-3 ◽

2020 ◽

Vol 10 (1) ◽

Author(s):

Hideaki Tsuyoshi ◽

Tetsuya Tsujikawa ◽

Shizuka Yamada ◽

Hidehiko Okazawa ◽

Yoshio Yoshida

Keyword(s):

Ovarian Cancer ◽

Fdg Pet ◽

Diagnostic Value ◽

Mri Contrast ◽

Diagnostic Potential ◽

Contrast Enhanced Ct ◽

Contrast Enhanced ◽

Imaging Results ◽

N Stage ◽

Sensitivity Specificity

Abstract Purpose To evaluate the diagnostic potential of PET/MRI with 2-[18F]fluoro-2-deoxy-d-glucose ([18F]FDG) in ovarian cancer. Materials and methods Participants comprised 103 patients with suspected ovarian cancer underwent pretreatment [18F]FDG PET/MRI, contrast-enhanced CT (ceCT) and pelvic dynamic contrast-enhanced MRI (ceMRI). Diagnostic performance of [18F]FDG PET/MRI and ceMRI for assessing the characterization and the extent of the primary tumor (T stage) and [18F]FDG PET/MRI and ceCT for assessing nodal (N stage) and distant (M stage) metastases was evaluated by two experienced readers. Histopathological and follow-up imaging results were used as the gold standard. The McNemar test was employed for statistical analysis. Results Accuracy for the characterization of suspected ovarian cancer was significantly better for [18F]FDG PET/MRI (92.5%) [95% confidence interval (CI) 0.84–0.95] than for ceMRI (80.6%) (95% CI 0.72–0.83) (p < 0.05). Accuracy for T status was 96.4% (95% CI 0.96–0.96) and 92.9% (95% CI 0.93–0.93) for [18F]FDG PET/MRI and ceMRI/ceCT, respectively. Patient-based accuracies for N and M status were 100% (95% CI 0.88–1.00) and 100% (95% CI 0.88–1.00) for [18F]FDG PET/MRI and 85.2% (95% CI 0.76–0.85) and 30.8% (95% CI 0.19–0.31) for ceCT and M staging representing significant differences (p < 0.01). Lesion-based sensitivity, specificity and accuracy for N status were 78.6% (95% CI 0.57–0.91), 95.7% (95% CI 0.93–0.97) and 93.9% (95% CI 0.89–0.97) for [18F]FDG PET/MRI and 42.9% (95% CI 0.24–0.58), 96.6% (95% CI 0.94–0.98) and 90.8% (95% CI 0.87–0.94) for ceCT. Conclusions [18F]FDG PET/MRI offers better sensitivity and specificity for the characterization and M staging than ceMRI and ceCT, and diagnostic value for T and N staging equivalent to ceMRI and ceCT, suggesting that [18F]FDG PET/MRI might represent a useful diagnostic alternative to conventional imaging modalities in ovarian cancer.

Download Full-text

211 Presentation of a Flims study: The diagnostic value of PET/CT for primary ovarian cancer–aprospective study

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)70186-7 ◽

2009 ◽

Vol 7 (2) ◽

pp. 54

Author(s):

S. Risum ◽

C. Hogdall ◽

A. Loft ◽

A.K. Berthelsen ◽

E. Hogdall ◽

...

Keyword(s):

Ovarian Cancer ◽

Diagnostic Value ◽

Primary Ovarian Cancer ◽

Pet Ct

Download Full-text

Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes

Translational Research ◽

10.1016/j.trsl.2018.10.003 ◽

2019 ◽

Vol 205 ◽

pp. 77-91 ◽

Cited By ~ 32

Author(s):

Lydia Giannopoulou ◽

Martha Zavridou ◽

Sabine Kasimir-Bauer ◽

Evi S. Lianidou

Keyword(s):

Ovarian Cancer ◽

Liquid Biopsy ◽

Circulating Mirnas

Download Full-text

Comparison of conventional, doppler and contrast-enhanced ultrasonography in differential diagnosis of ovarian masses: a systematic review and meta-analysis

BMJ Open ◽

10.1136/bmjopen-2021-052830 ◽

2021 ◽

Vol 11 (12) ◽

pp. e052830

Author(s):

Lizhang Xun ◽

Lamei Zhai ◽

Hui Xu

Keyword(s):

Systematic Review ◽

Ovarian Cancer ◽

Data Extraction ◽

Meta Analysis ◽

Diagnostic Value ◽

Doppler Us ◽

Contrast Enhanced ◽

Contrast Enhanced Ultrasonography ◽

Sensitivity Specificity ◽

Ovarian Masses

ObjectivesTo assess the value of conventional, Doppler and contrast-enhanced ultrasonography (CEUS) (conventional ultrasonography (US), Doppler US and CEUS) for diagnosing ovarian cancer.DesignSystematic review and meta-analysis.Data sourcesPubMed, Embase and the Cochrane Library were conducted for studies published until October 2021.Eligibility criteriaStudies assessed the diagnostic value of conventional US, Doppler US or CEUS for detecting ovarian cancer, with no restrictions placed on published language and status.Data extraction and synthesisThe study selection and data extraction were performed by two independent authors. The sensitivity, specificity, positive and negative likelihood ratio (PLR and NLR), diagnostic OR (DOR) and area under the receiver operating characteristic curve (AUC) were pooled using the bivariate generalised linear mixed model and random effects model.ResultsThe meta-analysis included 72 studies and involved 9296 women who presented with ovarian masses. The pooled sensitivity, specificity, PLR, NLR, DOR and AUC for conventional US were 0.91 (95% CI: 0.87 to 0.94) and 0.87 (95% CI: 0.82 to 0.91), 6.87 (95% CI: 4.98 to 9.49) and 0.10 (95% CI: 0.07 to 0.15), 57.52 (95% CI: 36.64 to 90.28) and 0.95 (95% CI: 0.93 to 0.97), respectively. The sensitivity, specificity, PLR, NLR, DOR and AUC for Doppler US were 0.93 (95% CI: 0.91 to 0.95) and 0.85 (95% CI: 0.80 to 0.89), 6.10 (95% CI: 4.59 to 8.11) and 0.08 (95% CI: 0.06 to 0.11), 61.76 (95% CI: 39.99 to 95.37) and 0.96 (95% CI: 0.94 to 0.97), respectively. The pooled sensitivity, specificity, PLR, NLR, DOR and AUC for CEUS were 0.97 (95% CI: 0.92 to 0.99) and 0.92 (95% CI: 0.85 to 0.95), 11.47 (95% CI: 6.52 to 20.17) and 0.03 (95% CI: 0.01 to 0.09), 152.11 (95% CI: 77.77 to 297.51) and 0.99 (95% CI: 0.97 to 0.99), respectively. Moreover, the AUC values for conventional US (p=0.002) and Doppler US (p=0.005) were inferior to those of CEUS.ConclusionsConventional US, Doppler US and CEUS have a relatively high differential diagnostic value for differentiating between benign and malignant ovarian masses. The diagnostic performance of CEUS was superior to that of conventional US and Doppler US.

Download Full-text